A total of 930 cases of ST-segment elevation myocardial infarction were prospectively recorded in the Florence health district. Factors influencing survival or those associated with use of revascularization (percutaneous coronary intervention, 91%) were identified through multivariate analyses (Cox and logistic regression, respectively). The independent protective effect of coronary reperfusion therapy (CRT) was evident at 36 months (39% reduction in the risk of death). After adjusting for all multivariate predictors, CRT use was 63% less likely at age 85 years and older than at under 65 years (p<0.001). Since beyond advancing age, comorbidity appeared to be associated with a reduced chance of CRT, three chronic comorbidity score categories were calculated using information on past medical history. Increased 1-year mortality in patients with higher comorbidity score categories derives, at least in part, from underutilization of CRT. Results confirm that although they might potentially benefit from CRT during ST-segment elevation myocardial infarction, older and frail patients are excluded from CRT, even when eligible.
Age and comorbidity in acute myocardial infarction: a report from the AMI-Florence Italian registry / Balzi D.; Barchielli A.; Buiatti E.; Franceschini C.; Mangani I.; Del Bianco L.; Monami M.; Valente S.; Gensini G.F.; Marchionni N.. - In: THE AMERICAN JOURNAL OF GERIATRIC CARDIOLOGY. - ISSN 1076-7460. - STAMPA. - 15:(2006), pp. 35-41. [10.1111/j.1076-7460.2006.05286.x]
Age and comorbidity in acute myocardial infarction: a report from the AMI-Florence Italian registry
Barchielli A.;Monami M.;Valente S.;Gensini G. F.;Marchionni N.
2006
Abstract
A total of 930 cases of ST-segment elevation myocardial infarction were prospectively recorded in the Florence health district. Factors influencing survival or those associated with use of revascularization (percutaneous coronary intervention, 91%) were identified through multivariate analyses (Cox and logistic regression, respectively). The independent protective effect of coronary reperfusion therapy (CRT) was evident at 36 months (39% reduction in the risk of death). After adjusting for all multivariate predictors, CRT use was 63% less likely at age 85 years and older than at under 65 years (p<0.001). Since beyond advancing age, comorbidity appeared to be associated with a reduced chance of CRT, three chronic comorbidity score categories were calculated using information on past medical history. Increased 1-year mortality in patients with higher comorbidity score categories derives, at least in part, from underutilization of CRT. Results confirm that although they might potentially benefit from CRT during ST-segment elevation myocardial infarction, older and frail patients are excluded from CRT, even when eligible.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.